國家衛生研究院 NHRI:Item 3990099045/7030
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 858747      線上人數 : 754
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/7030


    題名: Postoperative antiviral therapy with pegylated interferon plus ribavirin associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinoma
    作者: Hsu, YC;Lin, JT;Ho, HJ;Wu, MS;Wu, CY
    貢獻者: Division of Health Services and Preventive Medicine
    摘要: Background: Hepatocellular carcinoma (HCC) commonly recurs after surgical resection without effective adjuvant therapy. Pegylated interferon plus ribavirin has been shown efficacious in preventing the development of hepatitis C virus (HCV)-related HCC, but its efficacy in reducing HCC recurrence remains unknown. Objective: We aimed to investigate whether postoperative antiviral therapy reduced recurrence of HCVrelated HCC after resection. Methods: This population-based retrospective cohort study analyzed the Taiwan National Health Insurance Research Database. After screening 17,574 patients undergoing liver surgery for a first-time diagnosis of HCC between October 2003 and December 2008, we identified 893 patients with antiviral-na?ve HCV infection who had curative resection without recurrence within one year. Ninety five eligible patients received postoperative pegylated interferon plus ribavirin (treated cohort), and were matched 1:4 in age, gender, and cirrhosis status with 380 patients using no antiviral agent (untreated cohort). Patients were followed up for HCC recurrence and mortality since one year after surgery. Results: The HCC recurrence rate was significantly lower in the treated than the untreated cohort (32.39% versus 47.69% after 3 years of follow-up, p=0.004). With adjustment for multiple confounders including death occurring prior to HCC recurrence, the recurrence risk was reduced nearly by half (hazard ratio 0.52; 95% CI, 0.34-0.80) among treated patients. Multivariate stratified analyses confirmed antiviral therapy was consistently associated with attenuated risk of HCC recurrence across subgroups. Moreover, mortality was lower in the treated cohort significantly (1.92% vs. 17.68% after 3 years of follow-up, p=0.004). Conclusions: Postoperative pegylated interferon plus ribavirin is associated with reduced recurrence of surgically resected HCV-related HCC.
    日期: 2012-10
    關聯: Hepatology. 2012 Oct;56(Suppl. 1):276A.
    Link to: http://dx.doi.org/10.1002/hep.26040
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0270-9139&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000310955601165
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84867585259
    顯示於類別:[林肇堂] 會議論文/會議摘要

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    ISI000310955601165.pdf63KbAdobe PDF796檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋